DOCSLIB.ORG

Synthesis and Evaluation of a Novel Carbohydrate Template and Analogs Thereof for Potential CNS- Active Drugs Emi Hanawa-Romero [email protected]

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Synthesis and Evaluation of a Novel Carbohydrate Template and Analogs Thereof for Potential CNS- Active Drugs Emi Hanawa-Romero Emi.Hanawa@Student.Shu.Edu Seton Hall University eRepository @ Seton Hall Seton Hall University Dissertations and Theses Seton Hall University Dissertations and Theses (ETDs) Spring 5-15-2017 Synthesis and Evaluation of A Novel Carbohydrate Template and Analogs Thereof for Potential CNS- active Drugs Emi Hanawa-Romero [email protected] Follow this and additional works at: https://scholarship.shu.edu/dissertations Part of the Carbohydrates Commons, Medicinal Chemistry and Pharmaceutics Commons, and the Organic Chemicals Commons Recommended Citation Hanawa-Romero, Emi, "Synthesis and Evaluation of A Novel Carbohydrate Template and Analogs Thereof for Potential CNS-active Drugs" (2017). Seton Hall University Dissertations and Theses (ETDs). 2279. https://scholarship.shu.edu/dissertations/2279 Synthesis and Evaluation of A Novel Carbohydrate Template and Analogs Thereof for Potential CNS-active Drugs by Emi Hanawa-Romero Submitted in partial fulfillment of the requirements for the degree Doctor of Philosophy Department of Chemistry and Biochemistry Seton Hall University May 2017 i © 2017 Emi Hanawa-Romero ii Acknowledgements I am very much thankful to my mentor, Prof. Cecilia Marzabadi, for her support and guidance, throughout the program. Her mentorship filled with enormous experience and knowledge, as well as her pleasant personality made this dissertation happen. She has always been there for me, whenever I encounter problems, and her perpetual encouragement made may PhD years consequential and enjoyable. I am grateful to the Department of Chemistry and Biochemistry for providing me the opportunity to pursue my PhD in Chemistry. I would also like to thank Prof. James Hanson and Fr. Gerald Buonopane for their support and encouragement. Their advices improved my understanding in science and the quality of my work for the entirely. I always enjoyed listening to the stories behind chemistry and science that are provide from Prof. Hanson and Fr. Gerry. I am also grateful to the opportunity to teach under Prof. Marzabadi and Prof. Hanson in organic chemistry lab. I am thankful to the Center for Applied Catalysis at Seton Hall University, especially Prof. Robert Augustine and Dr. Setrak Tanielyan, for their expertise and providing a special facility to conduct some reactions. I would also like to acknowledge Prof. Murphy, Prof. Gorun and Prof. Sabatino with the maintenance of NMR facilities. I am also thankful to Ms. Maureen Grutt, Mr. David Edwards and Mr. Rafael Rivera for their assistance. I am also grateful for Robert DeSimone Graduate Fellowship for partial financial support. I would like to acknowledge that receptor binding profiles, agonist and/or antagonist functional data and Ki determinations were generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program, Contract # iv HHSN-271-2013-00017-C (NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscoll at NIMH, Bethesda MD, USA. High resolution mass spectrometry was performed at Mass Spectroscopy Laboratory at University of Illinois at Urbana- Champaign, Urbana, IL, USA. I am particularly thankful to the director at MS lab, Mr. Furong Sun, for prompt support and the effort to solve problems in a timely manner, when I inquired. I could not have completed this dissertation without immeasurable support of my family and friends. Notably, I would like to thank my parents Munenori and Toyoko, for supporting my dream and encouraging me for every single decision I made. I would also like to thank my brother Akihito, my father-in-law Ricardo, my uncles Michael and Jerome Frank, my aunts Molly and Helen Frank for all their support. Last, but certainly not least, I would like to thank my husband Paul. He supported me from my early year in this program until the very end. I am incredibly grateful to his understanding in regard to my passion in science and irregular schedule associated with chemistry. Coming home to receive warm welcomes every day from Paul as well as Leo, Rusty, Argos and Gizmo assisted me to go through rough days and made this dissertation happen. v Table of Contents Acknowledgements iv List of Tables viii List of Schemes ix List of Figures xi Abbreviations xiv Abstract xix Chapter 1. An Introduction to Central Nervous System Disorders and the Drugs Used to Treat Them 1.1. Introduction 1 1.2. Addiction 11 1.3. Epilepsy 14 1.4. Parkinson’s Disease 19 1.5. CNS-Active Drugs 24 1.6. Summary 30 Chapter 2. Synthesis of A Novel Carbohydrate Template and Its Analogs for the Treatment of Addiction, Epilepsy, Parkinson’s Disease and other CNS Disorders 2.1. Introduction 32 2.2. Background 37 vi 2.3. Results: Chemistry 39 2.4. Summary 74 Chapter 3. Evaluation of A Novel Carbohydrate Template and Its Analogs for the Treatment of Addiction, Epilepsy, Parkinson’s Disease and other CNS Disorders 3.1. Introduction 77 3.2. Background 85 3.3. Results: Physicochemical Properties 87 3.4. Results: Biological Activity and SAR Analysis 91 3.5. Summary 125 Chapter 4. Conclusions 4.1. Conclusions 127 Chapter 5. Experimental 5.1. Experimental 131 References 159 Appendix – NMR Spectra 177 vii List of Tables Table 2.1. Various reaction conditions for solution based benzylidenation of D-glucal with p-anisaldehyde dimethylacetal. Table 2.2. Results of Imine, Oxime and Hydrazone Derivatives. Table 2.3. Results of Acetalization/Ketalization Derivatives. Table 3.1. Calculated Physicochemical Properties of the Series of Novel Carbohydrate Benzylidene Derivatives. Table 3.2. Primary Binding Assay Results. Table 3.3. Primary Functional Results – mGluRs. viii List of Schemes Scheme 1.1. Biosynthesis of L-DOPA. Scheme 2.1. Syntheses of Tri-O-acetyl-D-glucal 15. Scheme 2.2. Synthesis of Compound 12. Scheme 2.3. Acid Catalyzed Reactions Associated with Benzylidenation of Glycals. Scheme 2.4. Attempts at Basic Benzylidenation. Scheme 2.5. An alternative synthetic route of benzylidene glycal. Scheme 2.6. A Novel Carbohydrate Template and Sites of Modifications. Scheme 2.7. Deoxy Derivatives. Scheme 2.8. Type II Ferrier Rearrangement Derivatives. Scheme 2.9. Synthesis of C3 Derivatives – Hydrophobic Modifications. Scheme 2.10. C3 Derivatives – Conjugated Ketone 46. Scheme 2.11. C3 Derivatives – Imines, Oximes and Hydrazones. Scheme 2.12. C3 Derivatives – Attempted Fluorinations. Scheme 2.13. C3 Derivatives – Attempted Synthesis of a Thioketone Derivative. Scheme 2.14. Attempted Formation of an Allal Derivative 58. Scheme 2.15. Syntheses of Galactal Derivatives. ix Scheme 2.16. Syntheses of Acetalization/Ketalization Derivatives. Scheme 2.17. Syntheses of Ether Derivatives. x List of Figures Figure 1.1. The Number of New Patients in the U.S. in 2013. Figure 1.2. Age-adjusted death rates for selected causes of death for all ages, by sex: United States, 2004-2014. Figure 1.3. The Number of Drugs Approved by the FDA in 2015. Figure 1.4. The FDA Approval Duration and Rate: CNS vs. non-CNS Drugs. Figure 1.5. Percentage of Total Disability-Adjusted Life Years (DALYs) Lost from Diseases. Figure 1.6. Structures of Methamphetamine, Caffeine and Methylphenidate. Figure 1.7. Structures of Tetrahydrocannabinol and Cannabidiol. Figure 1.8. General Structure of Benzodiazepine. Figure 2.1. Components of the Blood Brain Barrier. Figure 2.2. Markush Structures of Novel Cyclopropanated Carbohydrates. Figure 2.3. Structure of Lead Molecule 12. Figure 2.4. Structures of Morphine and Derivatives Thereof. Figure 3.1. Pentameric Structure of GABAA Receptor and Binding Sites. Figure 3.2. Examples of Ligands of GABAA Receptor. Figure 3.3. Examples of Ligands of mGluR5. xi Figure 3.4. Examples of Ligands of D2-like Dopamine Receptors and Norepinephrine Transporter. Figure 3.5. Examples of Ligands of Muscarinic Acetylcholine Receptors. Figure 3.6. Examples of Ligands of 5-HTs. Figure 3.7. Examples of Ligands of Sigma 2 Receptor. Figure 3.8. Secondary Binding Results – mGluR5. Figure 3.9. Secondary Functional Results – mGluR5. Figure 3.10. Structures of Compounds Used for mGluR5 Tests. Figure 3.11. Secondary Binding Results – D2-like Dopamine Receptors. Figure 3.12. Secondary Functional Results – D3. Figure 3.13. Secondary Functional Results – D4. Figure 3.14. Structures of Compounds Used for D2-like Receptors Test. Figure 3.15. Secondary Binding Result – NET. Figure 3.16. Structures of Compounds Used for NET Test. Figure 3.17. Secondary Binding Result – M2. Figure 3.18. Secondary Binding Result – M4. Figure 3.19. Structures of Compounds Used for M2&4 Receptors Test. Figure 3.20. Secondary Binding Result – 5HT2B. Figure 3.21. Secondary Binding Result – 5HT6. xii Figure 3.22. Structures of Compounds Used for 5-HT Receptors Tests. Figure 3.23. Secondary Binding Result – Sigma 2. Figure 3.24. Structures of Compounds Used for Sigma 2 Receptor Tests. xiii Abbreviations AD = Alzheimer’s disease ADHD = attention deficit/hyperactivity disorder AIBN = Azobisisobutyronitrile AIDS = acquired immune deficiency syndrome AMPA = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ASD = autism spectrum disorder Aβ = amyloid β-peptides BBB = Blood-brain barrier BZD = benzodiazepine cAMP = cyclic adenosine monophosphate CCR5 = C-C chemokine receptor type 5 clogP = Calculated logP CNS = Central nervous system CT = computed tomography D1-5 = dopamine receptors 1-5 DALY = disability-adjusted life years xiv DCM = Dichloromethane DMF = Dimethylformamide DTG = ditolylguanidine EC80 = 80% effective concentration EEG = electroencephalogram FMR1
Load more

Recommended publications
  • Review of Market for Octane Enhancers
    May 2000 • NREL/SR-580-28193 Review of Market for Octane Enhancers Final Report J.E. Sinor Consultants, Inc. Niwot, Colorado National Renewable Energy Laboratory 1617 Cole Boulevard Golden, Colorado 80401-3393 NREL is a U.S. Department of Energy Laboratory Operated by Midwest Research Institute • Battelle • Bechtel Contract No. DE-AC36-99-GO10337 May 2000 • NREL/SR-580-28193 Review of Market for Octane Enhancers Final Report J.E. Sinor Consultants, Inc. Niwot, Colorado NREL Technical Monitor: K. Ibsen Prepared under Subcontract No. TXE-0-29113-01 National Renewable Energy Laboratory 1617 Cole Boulevard Golden, Colorado 80401-3393 NREL is a U.S. Department of Energy Laboratory Operated by Midwest Research Institute • Battelle • Bechtel Contract No. DE-AC36-99-GO10337 NOTICE This report was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or any agency thereof. Available electronically at http://www.doe.gov/bridge Available for a processing fee to U.S.
    [Show full text]
  • Formation of Highly Oxygenated Organic Molecules from Aromatic Compounds
    Formation of highly oxygenated organic molecules from aromatic compounds. Ugo Molteni1, Federico Bianchi1-2, Felix Klein1, Imad El Haddad1, Carla Frege1, Michel J. Rossi1, Josef Dommen1, Urs Baltensperger1,* 5 1Laboratory of Atmospheric Chemistry, Paul Scherrer Institute, CH-5232 Villigen, Switzerland 2Department of Physics, University of Helsinki, 00014 Helsinki, Finland Correspondence to: Urs Baltensperger ([email protected]) Abstract 10 Anthropogenic volatile organic compounds (AVOC) often dominate the urban atmosphere and consist to a large degree of aromatic hydrocarbons (ArHC), such as benzene, toluene, xylenes, and trimethylbenzenes, e.g. from handling and combustion of fuels. These compounds are important precursors for the formation of secondary organic aerosol. Despite their recognized importance as atmospheric reactants, the formation of highly oxygenated molecules (HOMs) in the gas phase leading to (extremely) low volatility compounds has not been studied in the past. Here we show that oxidation of 15 aromatics with OH leads to a subsequent autoxidation chain reaction forming HOMs with an O:C ratio of up to 1.09. This is exemplified for five single-ring ArHC (benzene, toluene, o-/m-/p-xylene, mesitylene (1,3,5-trimethylbenzene) and ethylbenzene), as well as two conjugated polycyclic ArHC (naphthalene and biphenyl). We present the identified compounds, differences in the observed oxidation patterns and discuss mechanistic pathways. We report the elemental composition of the HOMs and show the differences in the oxidation patterns of these ArHCs. A potential pathway for the 20 formation of these HOMs from aromatics is presented and discussed. We hypothesize that AVOC may contribute substantially to new particle formation events that have been detected in urban areas.
    [Show full text]
  • A Role for Sigma Receptors in Stimulant Self Administration and Addiction
    Pharmaceuticals 2011, 4, 880-914; doi:10.3390/ph4060880 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review A Role for Sigma Receptors in Stimulant Self Administration and Addiction Jonathan L. Katz *, Tsung-Ping Su, Takato Hiranita, Teruo Hayashi, Gianluigi Tanda, Theresa Kopajtic and Shang-Yi Tsai Psychobiology and Cellular Pathobiology Sections, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, MD, 21224, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]. Received: 16 May 2011; in revised form: 11 June 2011 / Accepted: 13 June 2011 / Published: 17 June 2011 Abstract: Sigma1 receptors (σ1Rs) represent a structurally unique class of intracellular proteins that function as chaperones. σ1Rs translocate from the mitochondria-associated membrane to the cell nucleus or cell membrane, and through protein-protein interactions influence several targets, including ion channels, G-protein-coupled receptors, lipids, and other signaling proteins. Several studies have demonstrated that σR antagonists block stimulant-induced behavioral effects, including ambulatory activity, sensitization, and acute toxicities. Curiously, the effects of stimulants have been blocked by σR antagonists tested under place-conditioning but not self-administration procedures, indicating fundamental differences in the mechanisms underlying these two effects. The self administration of σR agonists has been found in subjects previously trained to self administer cocaine. The reinforcing effects of the σR agonists were blocked by σR antagonists. Additionally, σR agonists were found to increase dopamine concentrations in the nucleus accumbens shell, a brain region considered important for the reinforcing effects of abused drugs.
    [Show full text]
  • Cerebellar Toxicity of Phencyclidine
    The Journal of Neuroscience, March 1995, 75(3): 2097-2108 Cerebellar Toxicity of Phencyclidine Riitta N&kki, Jari Koistinaho, Frank Ft. Sharp, and Stephen M. Sagar Department of Neurology, University of California, and Veterans Affairs Medical Center, San Francisco, California 94121 Phencyclidine (PCP), clizocilpine maleate (MK801), and oth- Phencyclidine (PCP), dizocilpine maleate (MK801), and other er NMDA antagonists are toxic to neurons in the posterior NMDA receptor antagonistshave attracted increasing attention cingulate and retrosplenial cortex. To determine if addition- becauseof their therapeutic potential. These drugs have neuro- al neurons are damaged, the distribution of microglial ac- protective properties in animal studies of focal brain ischemia, tivation and 70 kDa heat shock protein (HSP70) induction where excitotoxicity is proposedto be an important mechanism was studied following the administration of PCP and of neuronal cell death (Dalkara et al., 1990; Martinez-Arizala et MK801 to rats. PCP (10-50 mg/kg) induced microglial ac- al., 1990). Moreover, NMDA antagonists decrease neuronal tivation and neuronal HSP70 mRNA and protein expression damage and dysfunction in other pathological conditions, in- in the posterior cingulate and retrosplenial cortex. In ad- cluding hypoglycemia (Nellgard and Wieloch, 1992) and pro- dition, coronal sections of the cerebellar vermis of PCP (50 longed seizures(Church and Lodge, 1990; Faingold et al., 1993). mg/kg) treated rats contained vertical stripes of activated However, NMDA antagonists are toxic to certain neuronal microglial in the molecular layer. In the sagittal plane, the populations in the brain. Olney et al. (1989) demonstratedthat microglial activation occurred in irregularly shaped patch- the noncompetitive NMDA antagonists,PCP, MK801, and ke- es, suggesting damage to Purkinje cells.
    [Show full text]
  • 11.8 Aromatic Compounds Aromatic Compounds Naming Aromatic
    11.8 Aromatic Compounds In 1825, Michael Faraday isolated a hydrocarbon called benzene, which consists of a six-carbon ring with alternating double bonds and has the molecular formula C6H6. Learning Goal Describe the bonding in benzene; name aromatic compounds, and draw their skeletal formulas. Chemistry: An Introduction to General, Organic, and Biological Chemistry, Twelfth Edition © 2015 Pearson Education, Inc. Aromatic Compounds Benzene is • an aromatic compound • a ring of six C atoms, each bonded to one H atom • a flat ring structure drawn with three alternating double bonds • represented by two structures because the electrons are shared equally among all the C atoms • represented by a skeletal formula using a circle in the center instead of the alternating double bonds Chemistry: An Introduction to General, Organic, and Biological Chemistry, Twelfth Edition © 2015 Pearson Education, Inc. Naming Aromatic Compounds Aromatic compounds containing a benzene ring and a single substituent are named as benzene derivatives. Since the ring contains only one substituent, the ring is not numbered. Some common names such as toluene, aniline, and phenol are allowed by IUPAC rules. Chemistry: An Introduction to General, Organic, and Biological Chemistry, Twelfth Edition © 2015 Pearson Education, Inc. 1 Naming Aromatic Compounds When there are two or more substituents, the benzene ring is numbered to give the lowest numbers to the substituents. Chemistry: An Introduction to General, Organic, and Biological Chemistry, Twelfth Edition © 2015 Pearson Education, Inc. Naming Aromatic Compounds When a common name such as toluene, phenol, or aniline can be used, • the carbon atom attached to the methyl, hydroxyl, or amine group is numbered as carbon 1 • the other substituents are named alphabetically Chemistry: An Introduction to General, Organic, and Biological Chemistry, Twelfth Edition © 2015 Pearson Education, Inc.
    [Show full text]
  • Gαq-ASSOCIATED SIGNALING PROMOTES NEUROADAPTATION to ETHANOL and WITHDRAWAL-ASSOCIATED HIPPOCAMPAL DAMAGE
    University of Kentucky UKnowledge Theses and Dissertations--Psychology Psychology 2015 Gαq-ASSOCIATED SIGNALING PROMOTES NEUROADAPTATION TO ETHANOL AND WITHDRAWAL-ASSOCIATED HIPPOCAMPAL DAMAGE Anna R. Reynolds Univerity of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Reynolds, Anna R., "Gαq-ASSOCIATED SIGNALING PROMOTES NEUROADAPTATION TO ETHANOL AND WITHDRAWAL-ASSOCIATED HIPPOCAMPAL DAMAGE" (2015). Theses and Dissertations--Psychology. 74. https://uknowledge.uky.edu/psychology_etds/74 This Doctoral Dissertation is brought to you for free and open access by the Psychology at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Psychology by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless an embargo applies.
    [Show full text]
  • Patterns of Antipsychotic Prescription to Patients with Schizophrenia in Korea: Results from the Health Insurance Review & Assessment Service-National Patient Sample
    ORIGINAL ARTICLE Psychiatry & Psychology http://dx.doi.org/10.3346/jkms.2014.29.5.719 • J Korean Med Sci 2014; 29: 719-728 Patterns of Antipsychotic Prescription to Patients with Schizophrenia in Korea: Results from the Health Insurance Review & Assessment Service-National Patient Sample Seon-Cheol Park,1,2 Myung-Soo Lee,3 This study aimed to analyze the patterns of antipsychotic prescription to patients with Seung-Gul Kang,4 and Seung-Hwan Lee5 schizophrenia in Korea. Using the Health Insurance Review & Assessment Service-National Patients Sample (HIRA-NPS), which was a stratified sampling from the entire population 1 Department of Psychiatry, Yong-In Mental Hospital, under the Korean national health security system (2009), descriptive statistics for the Yongin; 2Institute of Mental Health, Hanyang University, Seoul; 3Seoul Mental Health Center & patterns of the monopharmacy and polypharmacy, neuropsychiatric co-medications, and Seoul Suicide Prevention Center, Seoul; 4Department prescribed individual antipsychotic for patients with schizophrenia were performed. of Psychiatry, Gachon University, School of Comparisons of socioeconomic and clinical factors were performed among patients 5 Medicine, Incheon; Department of Psychiatry, Inje prescribed only with first- and second-generation antipsychotics. Of 126,961 patients with University Ilsan Paik Hospital, Goyang, Korea schizophrenia (age 18–80 yr), 13,369 were prescribed with antipsychotic monopharmacy Received: 19 December 2013 and the rest 113,592 with polypharmacy. Two or more antipsychotics
    [Show full text]
  • Alkylation of Aromatic Hydrocarbons with Divinylbenzene by Solid Polymeric Oxo Acids
    Polymer Journal, Vol. 13, No.9, pp 915-917 (1981) NOTE Alkylation of Aromatic Hydrocarbons with Divinylbenzene by Solid Polymeric Oxo Acids Hiroshi HASEGAWA and Toshinobu HIGASHIMURA Department of Polymer Chemistry, Kyoto University, Kyoto 606, Japan. (Received February 28, 1981) KEY WORDS Solid Polymeric Oxo Acid I Alkylation I Bis(l-arylethyl)- benzene I Nafion-H I Amberlyst 151 Divinylbenzene I Aromatic Hydrocar­ bons I In our recent papers on the alkylation of aromatic hydrocarbons with styrene (eq 1),u we have shown that solid polymeric oxo acids as catalysts can bring about higher yields of 1-phenyl-1-arylethane (I) than the corresponding soluble oxo acids [e.g., poly(styrenesulfonic acid) (Amberlyst 15) vs. p­ CH3C6H4S03H; perfluorinated resinsulfonic acid (Nafion-H) vs. CF S0 H]. In view of the easy 3 3 yH3 yH3 separation of the product from the catalyst, the use (2) of these effective polymeric oxo acids should be H H industrially more advantageous than homogeneous (II) processes using soluble acidic catalysts. H H EXPERIMENTAL ) CH3-t-Ar + ift' CH2© ) Aromatic Hydrocarbons © Materials (I) (1) The DVB used in most experiments was an isomeric mixture (m-DVB/p-DVB = 70/30, purity;::: This article deals with the alkylation of aromatic 98%) separated from a commercial mixture of hydrocarbons (toluene and m-xylene) with divinyl­ DVB (60%) and ethylvinylbenzene (40%) by benzene (DVB) catalyzed by solid polymeric oxo preparative liquid chromatography.5 p-DVB and m­ acids (Nafion-H and Amberlyst 15). If the two vinyl DVB were isolated from the commercial mixture by groups in DVB, as in the case of styrene, react the method of Storey et a/.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • MO STUDIES of SOME NONBENZENOID AROMATIC SYSTEMS Electrons
    MO STUDIESOFSOME NONBENZENOID AROMATIC SYSTEMS MIcL J. S. DEWAR Department of Chemistry, The University of Texas at Austin, Austin, Texas 78712, USA ABSTRACT A new version of(MINDO/3) of the MINDO semiempirical SCF MO method has been developed which seems to avoid the serious defects of earlier treat- ments. Very extensive tests show that it gives results at least comparable with those of the best ab initio SCF procedures at one-hundred-thousandth of the cost. Calculations are reported for the benzynes, for various cyclic polymethines, including (CH), (CH)3, (CH), (CH)4, (CH), (CH)5, (CH), (CI{), and (CH)18, for azulene and pentalene, for the cycloheptatriene—norcaradiene equilibrium, for spironoatetraene, for silabenzene, for a variety of poly- azines and polyazoles, and for various aromatic and potentially aromatic sulphur-containing compounds. INTRODUCTION While theoretical organic chemistry has long been based on the results of quantum mechanical treatments, in particular simplified versions of the molecular orbital (MO) method, these until recently have been too inaccurate to give results of more than qualitative significance. Many problems have therefore remained outside the scope of current theory since their solution depended on quantitative estimates of the relative energies of atoms and molecules. Recently it has become possible to carry out such quantitative calculations and the results are already proving of major chemical interest in a number of areas. The purpose of this lecture is to report some preliminary studies of this kind of various aromatic systems and problems connected with them. There is of course no question of obtaining accurate solutions of the Schrodinger equation for molecules large enough to be of chemical interest.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Ep 0825173 A1
    Europaisches Patentamt (19) European Patent Office Office europeeneen des brevets £P 0 825 1 73 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) intci.6: C07C 67/317, C07C 69/76, 25.02.1998 Bulletin 1998/09 C07C 45/65, C07C 49/76, C07C 51/377, C07C 63/68, (21) Application number: 97306226.8 C07C 231/12, C07C 253/30 (22) Date of filing: 15.08.1997 (84) Designated Contracting States: (72) Inventors: AT BE CH DE DK ES Fl FR GB GR IE IT LI LU MC • Rayle, Heather Lynnette NL PT SE North Wales, Pennsylvania 19454 (US) Designated Extension States: • Stephens, Randell Wayne AL LT LV RO SI Perkasie, Pennsylvania 18944 (US) (30) Priority: 22.08.1996 US 24398 (74) Representative: Tanner, James Percival et al 16.06.1997 US ROHM AND HAAS (UK) LTD. European Operations Patent Department (71) Applicant: ROHM AND HAAS COMPANY Lennig House Philadelphia, Pennsylvania 19106-2399 (US) 2 Mason's Avenue Croydon CR9 3NB (GB) (54) Method for preparing aromatic compounds (57) A method for synthesizing aromatic com- substantially pure halogenated compounds from mix- pounds by selectively dehalogenating aromatic starting tures of starting materials. The method uses a copper materials is provided. Compounds may be prepared containing dehalogenation agent and an acid with the which are substituted with fluoro, chloro or bromo. The dehalogenation being controlled by a substituent such method may be used to remove halogen atoms from as a carboxylic acid, amide, ester, aldehyde, ketone or sites at which halogenation is not desired, and to form cyano on the aromatic ring.
    [Show full text]